Financial Instrument [Axis]
Corporate Debt Securities [Member]
Measurement Frequency [Axis]
Fair Value, Measurements, Recurring [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Business Acquisition [Axis]
EGEN Inc [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Purchase Agreement [Member]
Range [Axis]
Maximum [Member]
Award Type [Axis]
Stock Options [Member]
Restricted Stock Awards [Member]
Minimum [Member]
Legal Entity of Counterparty, Type [Axis]
Hisun [Member]
Loan Agreement [Member]
Legal Entity [Axis]
Horizon Technology Finance Corporation [Member]
Horizon Credit Agreement [Member]
Debt Instrument [Axis]
Class of Warrant or Right [Axis]
Horizon Warrants [Member]
Variable Rate [Axis]
LIBOR plus [Member]
IPR&D Drug Technology Platforms [Member]
Plan Name [Axis]
Inducement Option Grants [Member]
Title of Individual [Axis]
Five New Employees [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid in Capital [Member]
Treasury Stock [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
2018 Aspire Purchase Agreements [Member]
Sale of Stock [Axis]
Capital on DemandTM Sales Agreement [Member]
Geographical [Axis]
New Jersey [Member]
Asset Class [Axis]
Goodwill [Member]
IPR&D [Member]
Capital on Demand Agreement [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Noncompete Agreements [Member]
2018 Stock Incentive Plan [Member]
2007 Stock Incentive Plan [Member]
Adjustments for New Accounting Pronouncements [Axis]
Accounting Standards Update 2016-02 [Member]
Contingent Consideration by Type [Axis]
Glioblastoma Multiforme Brain Cancer [Member]
2018 Aspire Purchase Agreements [Member]
Equity Stock Awards [Member]
Inducement Awards [Member]
Income Statement Location [Axis]
Research and Development Expense [Member]
General and Administrative Expense [Member]
Amended Asset Purchase Agreement [Member]
Related Party Transaction [Axis]
10 Business Days of Achieving Milestone [Member]
Within One Year of Achieving Milestone [Member]
Fair Value Earnout Milestone Liability [Member]
Amended Asset Purchase Agreement Option Payment 1 [Member]
Amended Asset Purchase Agreement Option Payment 2 [Member]
Recognized Non-cash Charge [Member]
EGWU, Inc [Member]
1st Lease Amendment [Member]
First Year [Member]
2nd Lease Amendment [Member]
EGEN Asset Purchase Agreement [Member]
Revenue Ratably Through 2022 [Member]
Final Year [Member]
All Other Warrants [Member]
General and Administrative Expenses [Member]
Aspire Purchase Agreement [Member]
2019 Aspire Purchase Agreements [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business Flag
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Shell Company
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Investment securities - available for sale, at fair value
Accrued interest receivable on investment securities
Advances and deposits on clinical programs and other current assets
Total current assets
Property and equipment (at cost, less accumulated depreciation of $3,059,285 and $2,968,259, respectively)
Other assets:
In-process research and development, net
Goodwill
Operating lease right-of-use assets, net
Other intangible assets, net
Deposits and other assets
Total other assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable - trade
Other accrued liabilities
Notes payable - current portion, net of deferred financing costs
Operating lease liability - current portion
Deferred revenue - current portion
Total current liabilities
Earn-out milestone liability
Note Payable, net of deferred financing costs
Operating lease liability - non-current portion
Deferred revenue - non-current portion
Other liabilities - non-current
Total liabilities
Commitments and contingencies
Stockholders' equity:
Preferred Stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at September 30, 2019 and December 31, 2018)
Common stock - $0.01 par value (112,500,000 shares authorized; 22,002,752 and 18,832,168 shares issued at September 30, 2019 and December 31, 2018, respectively, and 22,002,418 and 18,831,834 shares outstanding at September 30, 2019 and December 31, 2018, respectively)
Additional paid-in capital
Accumulated other comprehensive gain
Accumulated deficit
Total stockholders' equity before treasury stock
Treasury stock, at cost (334 shares at September 30, 2019 and December 31, 2018)
Total stockholders' equity
Total liabilities and stockholders' equity
Accumulated depreciation and amortization of property, plant, and equipment
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Treasury stock, shares
Income Statement [Abstract]
Licensing revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other (expense) income:
Gain from change in valuation of earn-out milestone liability
Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments
Impairment of in-process research and development
Investment income
Interest expense
Other (expense) income
Total other (expense) income, net
Net loss
Net loss per common share
Basic and diluted
Weighted average shares outstanding
Basic and diluted
Statement of Comprehensive Income [Abstract]
Other comprehensive (loss) gain
Changes in:
Realized (gains) losses on investment securities recognized in investment income, net
Unrealized (losses) gains on investment securities, net
Change in unrealized (losses) gains on available for sale securities, net
Net loss
Comprehensive loss
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net loss to net cash from operating activities;
Depreciation and amortization
Change in fair value of earn-out milestone liability
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments
Impairment of in-process research and development
Recognition of deferred revenue
Stock-based compensation costs
Shares issued in exchange for services
Amortization of deferred finance charges and debt discount associated with notes payable
Change in deferred rent liability
Net changes in:
Accrued interest on investment securities
Advances, deposits and other current assets
Accounts payable and accrued liabilities
Net cash (used in) operating activities:
Cash flows from investing activities:
Purchases of investment securities
Proceeds from sale and maturity of investment securities
Purchases of property and equipment
Net cash provided by (used for) investing activities
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs
Proceeds received from notes payable, net of issuance costs
Net cash provided by financing activities
Decrease in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of cash flow information:
Interest paid
Cash paid for amounts included in measurement of lease liabilities:
Operating cash flows from lease payments
Non-cash financing and investing activities
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments
Fair value of common stock issued as equity issuance costs and charged against paid in capital
Fair value of warrants issued in connection with the debt facility
Right of use assets obtained in exchange for lease liabilities
Operating leases
Realized and unrealized gains and losses, net, on investment securities
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Sale of equity through ATM purchase agreement
Sale of equity through ATM purchase agreement, shares
Common stock and warrants to purchase common stock issued in connection with equity and debt facilities
Common stock and warrants to purchase common stock issued in connection with equity and debt facilities, shares
Common stock issued in connection with equity facilities
Common stock issued in connection with equity facilities, shares
Realized and unrealized gains and losses, net, on investments securities
Stock-based compensation expense
Issuance of restricted stock
Issuance of restricted stock, shares
Sale of equity through equity financing facilities
Sale of equity through equity financing facilities, shares
Common stock warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments
Balance
Balance, shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description
Basis of Presentation
Financial Condition and Business Plan
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements
Earnings Per Share [Abstract]
Net Loss Per Common Share
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments
Fair Value Measurements
Business Combinations [Abstract]
Acquisition of EGEN Assets
Payables and Accruals [Abstract]
Accrued Liabilities
Debt Disclosure [Abstract]
Note Payable
Equity [Abstract]
Stockholders' Equity
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation
Hercules Warrant [Member]
Earn-out Milestone Liability
Warrants and Rights Note Disclosure [Abstract]
Warrants
Leases [Abstract]
Leases
Technology Development And Licensing Agreements
Technology Development and Licensing Agreements
Schedule of Cost, Fair Value and Maturities of Short Term Investments
Schedule of Unrealized Losses and Fair Value of Investment Securities
Schedule of Investment Income
Schedule of Fair Value of Assets and Liabilities
Schedule of Future Amortization Amounts During the Remaining Life
Schedule of Fair Value of Assets Acquired
Schedule of Other Accrued Liabilities
Schedule of Future Principle Payments, Net of Unamortized Debt Discounts
Schedule of Stock Option Awards and Restricted Stock Grants
Schedule of Assumptions Used to Determine Fair Value of Options Granted
Schedule of Changes in Earn-out Milestone Liability
Schedule of Milestone Risk Adjustment Assessment
Summary of Warrant Activity
Schedule of Weighted Average Remaining Contractual Terms
Schedule of Lease Payments and Maturity of Our Operating Lease Liabilities
Statistical Measurement [Axis]
Cumulated net losses
Cash, investment securities and interest receivable
Tax benefits of EDA
Net cash proceeds for net operating loss
Unrecognized tax benefits
Net cash proceeds from receipts
Right-of-use assets
Operating lease liabilities
Reduced other liabilities
Number of shares of common stock issuable upon exercise of warrants and equity awards
Warrant exercise price
Warrant exercisable for common sock
Dividend payable
Short-term investments - Cost
Short-term investments - Fair Value
Short-term investment maturities - Within 3 months, cost
Short-term investment maturities - Between 3-12 months, cost
Total, cost
Short-term investment maturities - Within 3 months, fair value
Short-term investment maturities - Between 3-12 months, fair value
Total, fair value
Less than 12 months, unrealized holding (gains) losses, fair value
Less than 12 months, unrealized holding gains (losses), fair value
Investment securities - available for sale, at fair value
Less than 12 months, unrealized holding (gains) losses
Less than 12 months, unrealized holding gains (losses)
Unrealized holding gains (losses)
Interest and dividends accrued and paid
Realized gains
Investment income, net
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount
Fair Value, Net Derivative Asset (liability) Measured On Recurring Basis, Unobservable Inputs Reconciliation, Transfers Into Level 3
Investment securities, available for sale
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Total purchase price for asset acquisition
Potential future earn-out payments
Payments to acquire businesses, gross
Stock issued during period, shares, acquisitions
Indefinite lived intangible assets
Asset impairment charges, total
Business combination, consideration transferred, liabilities incurred
Finite-lived intangible assets acquired
Finite-lived intangible asset, useful life
Amortization expense
Finite-lived intangible assets, net
Finite-lived intangible assets, accumulated amortization
Goodwill, acquisition
2020
2021
2022 and thereafter
Total
Intangible assets, beginning balance
Amortization
Intangible assets, ending balance
Amounts due to contract research organizations and other contractual agreements
Accrued payroll and related benefits
Accrued professional fees
Other
Total
Line of credit facility, maximum borrowing capacity
Proceeds from lines of credit, total
Interest rate
Debt effective interest rate
Percentage of outstanding principle balance, description
Class of warrant or right exercisable
Debt instrument, unamortized discount, total
Financing fees and expenses
Loan origination fees
Percentage for original debt, amount
Interest expense, debt, total
Amortization of debt issuance costs
2020
2021
2022
2023 and thereafter
Subtotal of future principal payments
Unamortized debt issuance costs, net
Total
Shelf registration statement amount
Aggregate offering price, additions
Aggregate offering price, term
Maximum number of shares purchased per business day
Aggregate offering price
Aggregate offering price, description
Aspire purchase agreement, terms
Maximum number of shares purchased per business day, additional
Stock issued during period, shares, new issues
Proceeds from issuance of common stock
Commission percentage for gross proceeds from common stock
Aggregate value available for issuance
Equity awards, number of stock authorized
Number of equity awards available for future issuance
Percentage of fair market value of shares
Percentage of outstanding stock determining factor for incentive stock price
Number of shares issued
Inducement option grant, exercise price per share
Option vested period
Options expiration period
Number of shares reserved for future issuance
Compensation cost
Unrecognized compensation cost related to non-vested stock based compensation
Stock based compensation cost expected to be recognized, weighted average period
Weighted average grant date fair value of stock option awards granted
Number Outstanding, Outstanding, Beginning Balance
Number Outstanding, Equity awards granted
Number Outstanding, Vested and issued
Number Outstanding, Forfeited, cancelled or expired
Number Outstanding, Ending Balance
Number Outstanding, Exercisable
Weighted Average Exercise Price, Outstanding, Beginning Balance
Weighted Average Exercise Price, Equity awards granted
Weighted Average Exercise Price, Vested and issued
Weighted Average Exercise Price, Forfeited, cancelled or expired
Weighted Average Exercise Price, Outstanding, Ending Balance
Weighted Average Exercise Price, Exercisable
Weighted Average Remaining Contractual Term (years), Outstanding, Ending Balance
Weighted Average Remaining Contractual Term (years), Exercisable
Aggregate Intrinsic Value, Outstanding, Ending Balance
Aggregate Intrinsic Value, Exercisable
Non-vested stock awards outstanding, Beginning Balance
Non-vested stock awards outstanding, Equity awards granted
Non-vested stock awards outstanding, Vested and issued
Non-vested stock awards outstanding, Equity awards forfeited, cancelled or expired
Non-vested stock awards outstanding, Ending Balance
Non-vested stock awards outstanding, Aggregate intrinsic value, Ending Balance
Weighted Average Grant Date Fair Value, Beginning Balance
Weighted Average Grant Date Fair Value, Equity awards granted
Weighted Average Grant Date Fair Value, Vested and issued
Weighted Average Grant Date Fair Value, Forfeited, cancelled or expired
Weighted Average Grant Date Fair Value, Ending Balance
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Expected volatility, minimum
Expected volatility, maximum
Expected life (in years)
Expected dividend yield
Future earn-out payments
Fair value of Acquisition consideration
Risk adjusted assessment of each milestone
Estimated time to achieve the milestone
Earnout milestone liability
Warrants to purchase common stock
Warrants strike price
Warrants exercise price
Non-cash benefit
Gain (loss) from change in fair value of earn out milestone liability
Earn-out liabilities, beginning balance
Non-cash charge from the adjustment for the change in fair value included in net loss
Earn-out liabilities, ending balance
Risk-adjustment Assessment of achieving each Milestone
Discount Rate
Estimated Time to Achieve
Number of Warrants Issued, Warrants Outstanding, Beginning Balance
Number of Warrants Issued, Warrants Issued
Number of Warrants Issued, Warrants Expired
Number of Warrants Issued, Warrants Outstanding, Ending Balance
Aggregate Intrinsic Value of Outstanding Warrants
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance
Weighted Average Exercise Price, Warrants Issued
Weighted Average Exercise Price, Warrants Expired
Weighted Average Exercise Price, Warrants Outstanding and Exercisable, Ending Balance
Number of Warrants Issued
Weighted Average Exercise Price
Weighted Average Contractual Terms Remaining (in years)
Warrants Outstanding
Lease description
Lease expiration date
Lease, term of contract
Lease, renewal term
Lease, option to extend
Lease, rent payment
ROU asset
Other liabilities
Increased ROU asset
Operating lease costs
Operating cash flows from operating leases
Remainder of 2019
2020
2021
2022
2023
2024 and thereafter
Subtotal future lease payments
Less imputed interest
Total lease liabilities
Weighted average remaining life
Weighted average discount rate
Non-refundable research and development fee
Deferred revenue
Deferred revenue amortization period
Upfront payment
Represents Controlled Equity Offering Sales Agreement (the “ATM Agreement”) with Cantor Fitzgerald & Co., as sales agent.
Represents the additional aggregate offering price for shares of common stock that the Company may offer and sell through a sales agent.
Aggregate offering price, description.
Aggregate offering price, term.
Aggregate offering price.
Aspire Capital Fund, LLC [Member]
Aspire Purchase Agreement [Member]
The current amount of amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
Amount of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position.
Capital on Demand Agreement [Member]
Capital on DemandTM Sales Agreement [Member]
The amount of cash, investment securities and interest receivable.
Common Stock Sales Agreement [Member]
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) unrealized gain less than 12 months.
Amount of accumulated unrealized gain on investment in debt security measured at fair value with change in other comprehensive income (available-for-sale), unrealized gain for less than 12 months.
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three to twelve months.
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three to twelve months.
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with single maturity date and allocated without single maturity date, maturing in next rolling three months.
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three months.
Deferred finance charges.
The amortization period for deferred revenue.
Duke University [Member]
EGEN Asset Purchase Agreement [Member]
Information pertaining to the business acquisition of EGEN, Inc.
EGEN Inc [Member]
EGWU, Inc [Member]
The amount of earn-out milestone liability as of the balance sheet.
The disclosure related to earn-out milestone liabilities.
Equity Stock Awards [Member]
The amount of estimated time to achieve the milestone.
Exercise Agreements [Member]
Exercise Price One [Member]
Exercise Price Two [Member]
Fair value of common stock issued as equity issuance costs and charged against paid in capital.
Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments.
Fair value of warrants issued in connection with amendment to modify the related earn-out milestone payments.
Represents the public offering on February 14, 2017.
February 14, 2017 Public Offering [Member]
Federal Income Tax [Member]
First Tranche [Member]
Gain (loss) from change in valuation of earn-out milestone liability.
The amount of gain (loss) from the change in the fair value of earn-out milestone liability.
The amount recognized in earnings related to the change in fair value during the period of milestone liability.
Glioblastoma Multiforme Brain Cancer [Member]
Represents a loan agreement with Hercules Technology Growth Capital, Inc. (“Hercules”).
Represents Hercules Technology Growth Capital, Inc..
Hercules Technology Growth Capital, Inc. [Member]
Represents Hercules Technology Growth Capital, Inc..
Hisun Agreement [Member]
Hisun [Member]
Horizon Credit Agreement [Member]
Horizon Technology Finance Corporation [Member]
Horizon Warrants [Member]
Huntsville Alabama [Member]
IPR&D Drug Technology Platforms [Member]
IPR&D [Member]
In Process R and D - GBM Two [Member]
Inducement Option Grants [Member]
Investor Warrants [Member]
Represents the information pertaining to the direct offering agreement on July 6, 2017.
June 2016 Warrants [Member]
Lawrenceville New Jersey [Member]
License Agreement [Member]
The entire disclosure for a contractual arrangement, in which the Company gave another party an exclusive license.
Loan Agreement [Member]
Maximum number of shares purchased per day.
Maximum number of shares purchased per day, additional.
Represents a securities purchase agreement with certain investors into which the entity entered in May 2015.
New Jersey [Member]
Represents the total number of Shares of common stock issuable upon exercise of warrants and equity awards.
Represents the October 2017 Underwritten Offering.
Oppenheimer & Co. Inc. [Member]
Ovarian Cancer [Member]
Percentage of fair market value of shares
Percentage of outstanding stock determining factor for incentive stock price.
Information relating to Pre-Funded Series BB Warrant.
Represents the information pertaining to the Pre-Funded Series CCC Warrants.
Precentage of outstanding principle balance, description.
Purchase Agreement [Member]
Aspire purchase agreement, terms.
The percentage of risk-adjusted assessment of each milestone.
Sale of equity through equity financing facilities.
Sale of equity through equity financing facilities, shares.
The disclosure of transactions regarding the changes in earn-out liabilities during the period.
Tabular disclosure of the cost, fair value and maturities of short-term investments.
Second Tranche [Member]
Represents the information pertaining to the Series AAA Warrants.
Information relating to Series AA warrants.
Represents the information pertaining to the Series BBB Warrants.
Represents the information pertaining to Series DDD Warrants.
Weighted Average Exercise Price, Warrants issued
Number of Warrants Issued, Warrants issued.
Shares issued in exchange for services.
Shelf Registration statement.
Sale of equity through ATM purchase agreement, shares.
Sale of equity through ATM purchase agreement.
Tax benefits of EDA
Tax Reform Act [Member]
Three New Employees [Member]
2018 Stock Incentive Plan [Member]
2007 Stock Incentive Plan [Member]
Represents the information pertaining to the 2015 Warrants.
Represents the information pertaining to the 2013 Warrants, 2014 Warrants, and June 2016 Warrants.
U.S. Federal and State Tax [Member]
Underwriting Agreement [Member]
Warrant Exchange Agreements [Member]
Warrants [Text Block]
The tabular disclosure for share-based compensation, stock options and restricted stock awards, activity.
Tabular disclosure of the risk-adjustment assessment of each milestone.
Tabular disclosure of weighted average remaining contractual terms.
Net cash proceeds for net operating loss.
Aggregate value available for issuance.
Five New Employees [Member]
Inducement Awards [Member]
Earnout milestone liability.
Amended Asset Purchase Agreement [Member]
10 Business Days of Achieving Milestone [Member]
Within One Year of Achieving Milestone [Member]
Recognized Non-cash Benefit [Member]
Fair Value Earnout Milestone Liability [Member]
Amended Asset Purchase Agreement Option Payment 1 [Member]
Amended Asset Purchase Agreement Option Payment 2 [Member]
Recognized Non-cash Charge [Member]
Risk-adjustment Assessment of achieving each Milestone.
Discount Rate.
Other Warrant [Member]
1st Lease Amendment [Member]
2nd Lease Amendment [Member]
Upfront payment.
Revenue Ratably Through 2022 [Member]
Estimated Time to Achieve.
Reduction in Warrant [Member]
Commission percentage for gross proceeds from common stock.
First Year [Member]
Final Year [Member]
All Other Warrants [Member]
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
General and Administrative Expenses [Member]
Non-cash benefit.
Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value.
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.
Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.
Financial Condition and Business Plan [Text Block]
Class of warrant or right exercisable.
Fair value of warrants issued in connection with the debt facility.
Number Outstanding, Vested and issued.
Weighted Average Exercise Price, vested and issued.
Warrants strike price.
Common stock and warrants to purchase common stock issued in connection with equity and debt facilities.
Common stock and warrants to purchase common stock issued in connection with equity and debt facilities, shares.
Net cash proceeds from receipts.
2018 Aspire Purchase Agreements [Member]
2018 Aspire Purchase Agreements [Member]
2019 Aspire Purchase Agreements [Member]
Impairment of in-process research and development.
AspirePurchaseAgreementsMember
Assets, Current
Assets, Noncurrent
Assets
Liabilities, Current
Liabilities
Stockholders' Equity before Treasury Stock
Treasury Stock, Value
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Nonoperating Income (Expense)
Weighted Average Number of Shares Outstanding, Basic and Diluted
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Loss from change in valuation of earn-out milestone liability
Contract with Customer, Liability, Revenue Recognized
Increase (Decrease) in Accrued Investment Income Receivable
Increase (Decrease) in Deposit Assets
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Available-for-sale Securities
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Shares, Outstanding
Cost
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value
Less than 12 months, unrealized gains, fair value
Less than 12 months, unrealized gains
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Unrealized gains (losses)
Amortization of Intangible Assets
Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two
Long-term Debt, Gross
Debt Instrument, Unamortized Discount (Premium), Net
Long-term Debt
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
clsn_EarnoutMilestoneLiability
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne
Lessee, Operating Lease, Liability, Payments, Due Year Two
Lessee, Operating Lease, Liability, Payments, Due Year Three
Lessee, Operating Lease, Liability, Payments, Due Year Four
Lessee, Operating Lease, Liability, Payments, Due
Lessee, Operating Lease, Liability, Undiscounted Excess Amount